Workshop to accelerate the implementation of the Three I's for HIV/TB and earlier initiation of ART in Southern Africa
18 Mar 2011

Johannesburg, South Africa, 14-18 March 2011

WHO, in collaboration with the US Centers for Disease Control and Prevention (CDC) and the Office of the US global AIDS Coordinator (OGAC), conducted a five-day workshop in Johannesburg, South Africa, 14-18 March 2011, to accelerate the implementation of the Three I's for HIV/TB and earlier initiation of ART in Southern Africa. Participating countries were: Botswana, Lesotho, Mozambique, Namibia, South Africa, Swaziland, Zambia and Zimbabwe. The objectives of the meeting were to review the status of implementation of the Three I's for HIV/TB and earlier initiation of ART in the Region; share best practices and discuss enablers and challenges for nationwide scale-up; identify priority actions to improve recording and reporting formats and strengthen monitoring and evaluation; discuss the role of civil society; draft country specific action plans including priority actions to scale-up the Three I's for HIV/TB and earlier initiation of ART, and identify follow-up mechanisms. For further details, please click on the links below:

Workshop Report | Agenda | List of Participants | Presentations

TB/HIV summary from CROI 2011
27 Feb 2011

TB/HIV Research Frontiers meeting, 27 February, 2011 | Boston, USA

The Stop TB Department of the World Health Organization and the Consortium to Respond Effectively to the AIDS/TB Epidemic (CREATE) organized an HIV/TB research frontiers meeting on behalf of the TB/HIV Working Group of the Stop TB Partnership affiliated with the 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011) in Boston, USA on 27 February, 2010. This was the fifth in a series of annual meetings organized by WHO and CREATE in conjunction with CROI. The meeting was co-chaired by Dr Diane Havlir, the chair of the TB/HIV Working Group and Dr Richard Chaisson from Johns Hopkins University and CREATE, and was attended by about 80 HIV researchers and policy makers, including Ambassador Eric Goosby, the United States Global AIDS Coordinator.

The main objective of the meeting was to discuss emerging and unpublished data about the new Xpert MTB/RIF diagnostic tool and explore its implication in the diagnosis of TB among people living with HIV. The meeting also discussed the implication of the mouse model for the development of new TB drugs and explored its implication for people living with HIV. Dr Catharina Boehme from the Foundation for Innovative New Diagnostics (FIND) presented previously published and unpublished data on Xpert MTB/RIF, which has the sensitivity of a single Xpert test under routine conditions of 99% and 80% in smear positive culture positive and in smear negative culture positive specimens respectively. The performance of the test was not affected by HIV status. The use of Xpert resulted in shortening of time to case detection and treatment, and improved reporting of results as compared to routine practices. Preliminary results also showed that Xpert MTB/RIF perform better in those children living with HIV compared to HIV negative children. Results from preliminary studies also showed that Xpert performance is higher when used on extrapulmonary specimens except for cerebrospinal fluid. (See also a poster presented at the main conference describing the performance of Xpert MTB/RIF on fine-needle aspiration specimens with a sensitivity and specificity of 100% and 93.8% respectively (Van Rie, abstract 879, CROI 2011). Dr David Katzenstein of Stanford University, USA commented on Dr Boehme's presentation and underlined the role of the test in preventing the loss to follow up of patients after the first sputum test. He also urged on the importance of including INH resistance detection in the Xpert test.

Dr Eric Nuermberger of Johns Hopkins University presented data on the use of mouse model to develop new TB drugs and regimens and discussed its implication for people living with HIV. He described that the pathological differences between mice and humans have raised concerns about the "predictiveness" of mouse models in the development of new TB drugs. Nonetheless, mouse models represent the activity of existing TB drugs well and their careful use can inform TB drug development. Dr Annie Luetkemeyer from the University of California, San Francisco commented on the need to include people living with HIV in clinical trials and to improve surrogate markers to better predict the potency of new drugs and regimens.

TB/HIV at the main conference

The results of two randomized control trials on when to start ART in TB patients living with HIV were presented at the main conference. The STRIDE study compared immediate ART (2 weeks after TB treatment initiation) to early ART (within 8 to 12 weeks) among 806 people living with HIV with CD4 count <250 celles/mm3 recruited from study sites in Africa, Asia, Latin America and North America. The SAPIT trial compared two integrated arms of early (ART initiated within 4 weeks of TB treatment initiation) and late therapy (ART initiated within the first 4 weeks of the completion of TB treatment continuation phase i.e. at 12 weeks). Both studies showed that combined and earlier ART and TB treatment reduces death and AIDS related events with more pronounced effect among those people with CD4 count less than 50 cells/mm3. Death and AIDS events were significantly reduced in the immediate than the early arm in those with CD4 count <50 cells/mm3 by 42% and 68% in the STRIDE and SAPIT trials respectively. TB IRIS was significantly higher with immediate ART than early ART but no deaths were attributed to IRIS. A symposium entitled "Colliding epidemics: Controlling HIV-related TB" and co-convened by Drs Haileyesus Getahun of the Stop TB Department of WHO and Connie Benson of University of San Diego reviewed the management of patients requiring treatment for both TB and HIV diseasesadvances in TB diagnostics among people living with HIV, the use of preventive TB therapy, and the challenges and progress in understanding the immune response to TB infection for vaccine development.

New Rapid Diagnostic test Xpert MTB/RIF endorsed by WHO
1 Dec 2010

In December 2010, the World Health Organization (WHO) endorsed the new rapid diagnostic test for tuberculosis and rifampicin resistance named "Xpert MTB/RIF". This new diagnostic test promises to have a great impact on the community of people living with HIV. Evidence to date has shown that it could double the number of HIV-associated TB cases diagnosed in areas of high rates of TB and HIV. Click here for further information

New guidelines on Intensified Case Finding and Isoniazid Preventive Therapy for People Living with HIV in resource constrained settings
1 Dec 2010

These new guidelines were launched on 1st December, World Aids Day and aim to provide guidance to national AIDS and tuberculosis programmes and those providing HIV services to accelerate the nationwide implementation of IPT and ICF. They include evidence-based recommendations for adults, children and infants living with HIV, address implementation issues and identify key research gaps in order to scale up TB prevention, diagnosis and treatment as a core component of HIV prevention, treatment and care. They are aimed at policy-makers and health programme managers, governments, nongovernmental organizations, donors and patient support groups working in the field of HIV/AIDS and TB, and health-care workers providing care for people living with HIV. The new guidelines can be accessed here.